Comparative Pharmacology
Head-to-head clinical analysis: SANDOSTATIN versus SOMATULINE DEPOT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SANDOSTATIN versus SOMATULINE DEPOT.
SANDOSTATIN vs SOMATULINE DEPOT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic octapeptide analog of somatostatin with longer half-life. Inhibits growth hormone (GH), glucagon, and insulin secretion. Reduces splanchnic blood flow and suppresses serotonin release from neuroendocrine tumors.
Somatostatin analog; binds to somatostatin receptors (mainly SSTR2 and SSTR5) with high affinity, inhibiting the secretion of growth hormone (GH), insulin-like growth factor-1 (IGF-1), and various gastrointestinal hormones.
Subcutaneous: 50-100 mcg every 8-12 hours. Intravenous bolus: 50 mcg, then continuous infusion 25-100 mcg/hour for acute variceal bleeding.
90 mg subcutaneously every 4 weeks for acromegaly; 120 mg subcutaneously every 4 weeks for neuroendocrine tumors (administered every 2 weeks if progression occurs). Adjust dose based on clinical response and growth hormone/IGF-1 levels.
None Documented
None Documented
Terminal elimination half-life: 1.7–1.9 hours (subcutaneous); prolonged in hepatic impairment (up to 2.6 h). After intravenous bolus, biphasic elimination with t½ α ~0.2 h and t½ β ~1.5 h.
The terminal elimination half-life is approximately 23-29 days after subcutaneous injection of the depot formulation, supporting a monthly dosing interval.
Renal: ~32% unchanged; biliary/fecal: ~66% as metabolites; total clearance ~160 mL/min.
Lanreotide is primarily excreted via the biliary-fecal route. After administration, approximately 78% of a radiolabeled dose is recovered in feces, with less than 5% excreted unchanged in urine. The remainder is metabolized and eliminated via bile.
Category C
Category C
Somatostatin Analog
Somatostatin Analog